NYSE: CRLCharles River Laboratories International Revenue
Charles River Laboratories International revenue was $4.06B for the trailing 12 months ending Sep 28, 2024, with -13.4% growth year over year. Quarterly revenue for the quarter (Q3 2024) ending on Sep 28, 2024 was $1.0B, down 1.6% from last quarter. For the last reported fiscal year 2023 ending Dec 30, 2023, CRL annual revenue was $4.1B, with 3.9% growth year-over-year.
CRL past revenue growth
How has CRL's revenue growth performed historically?
Company
-3.67%
Industry
1.18%
Market
35.52%
CRL's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CRL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CRL's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
CRL revenue history
Current Revenue
$4.1B
Current Earnings
$413.1M
Current Profit Margin
10.2%
CRL's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when CRL announces revenue.
CRL Revenue History By Year
| CRL Yearly Revenue | CRL Revenue | CRL Change | CRL Revenue Growth |
|---|---|---|---|
| 2023-12-30 | $4.13B | $153.35M | +3.86% |
| 2022-12-31 | $3.98B | $435.90M | +12.31% |
| 2021-12-25 | $3.54B | $616.23M | +21.08% |
| 2020-12-26 | $2.92B | $302.71M | +11.55% |
| 2019-12-28 | $2.62B | $355.13M | +15.67% |
| 2018-12-29 | $2.27B | $408.50M | +21.99% |
| 2017-12-30 | $1.86B | $176.17M | +10.48% |
| 2016-12-31 | $1.68B | $318.13M | +23.34% |
| 2015-12-26 | $1.36B | $65.64M | +5.06% |
| 2014-12-27 | $1.30B | $132.13M | +11.34% |
| 2013-12-28 | $1.17B | $36.00M | +3.19% |
| 2012-12-29 | $1.13B | -$13.12M | -1.15% |
| 2011-12-31 | $1.14B | $9.23M | +0.81% |
| 2010-12-25 | $1.13B | -$38.23M | -3.26% |
| 2009-12-26 | $1.17B | -$123.66M | -9.55% |
| 2008-12-27 | $1.30B | $64.67M | +5.26% |
| 2007-12-29 | $1.23B | $172.24M | +16.27% |
| 2006-12-30 | $1.06B | $65.06M | +6.55% |
| 2005-12-31 | $993.33M | $269.11M | +37.16% |
| 2004-12-25 | $724.22M | $110.50M | +18.00% |
| 2003-12-27 | $613.72M | $59.09M | +10.65% |
| 2002-12-28 | $554.63M | $89.00M | +19.11% |
| 2001-12-29 | $465.63M | $159.05M | +51.88% |
| 2000-12-30 | $306.59M | $75.17M | +32.48% |
| 1999-12-25 | $231.41M | $26.35M | +12.85% |
| 1998-12-26 | $205.06M | $34.35M | +20.12% |
| 1997-12-27 | $170.71M | N/A | N/A |
Charles River Laboratories International Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.